Barrow, Hanley, Mewhinney & Strauss’s Elevance Health ELV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$119M Sell
407,168
-98,371
-19% -$32.3M 0.39% 74
2025
Q4
$177M Buy
505,539
+8,199
+2% +$2.77M 0.59% 60
2025
Q3
$161M Sell
497,340
-83,828
-14% -$26.1M 0.51% 62
2025
Q2
$226M Sell
581,168
-689,426
-54% -$277M 0.76% 53
2025
Q1
$553M Buy
1,270,594
+487,672
+62% +$196M 2.01% 11
2024
Q4
$289M Sell
782,922
-67,718
-8% -$28.3M 0.98% 41
2024
Q3
$442M Sell
850,640
-382,829
-31% -$205M 1.45% 26
2024
Q2
$668M Sell
1,233,469
-38,447
-3% -$20.3M 2.28% 8
2024
Q1
$660M Sell
1,271,916
-95,516
-7% -$47.5M 2.22% 9
2023
Q4
$645M Sell
1,367,432
-3,803
-0.3% -$1.76M 2.27% 9
2023
Q3
$597M Buy
1,371,235
+132,432
+11% +$60.1M 2.28% 9
2023
Q2
$550M Sell
1,238,803
-33,823
-3% -$15.6M 2.05% 12
2023
Q1
$585M Sell
1,272,626
-180,010
-12% -$85.7M 2.26% 7
2022
Q4
$745M Sell
1,452,636
-54,426
-4% -$27.6M 2.8% 4
2022
Q3
$685M Sell
1,507,062
-106,153
-7% -$50.8M 2.81% 4
2022
Q2
$779M Sell
1,613,215
-26,697
-2% -$13.2M 2.94% 4
2022
Q1
$806M Sell
1,639,912
-111,865
-6% -$51.1M 2.63% 3
2021
Q4
$812M Sell
1,751,777
-91,021
-5% -$38.3M 2.57% 2
2021
Q3
$687M Buy
1,842,798
+30,017
+2% +$11.4M 2.28% 7
2021
Q2
$692M Buy
1,812,781
+163,444
+10% +$62.5M 2.22% 8
2021
Q1
$592M Buy
1,649,337
+136,537
+9% +$43.9M 1.89% 13
2020
Q4
$486M Sell
1,512,800
-54,935
-4% -$16.9M 1.67% 23
2020
Q3
$421M Sell
1,567,735
-41,428
-3% -$11.1M 1.62% 25
2020
Q2
$423M Sell
1,609,163
-191,020
-11% -$51M 1.66% 21
2020
Q1
$409M Buy
1,800,183
+88,746
+5% +$24.2M 1.87% 18
2019
Q4
$517M Sell
1,711,437
-1,905,345
-53% -$524M 1.65% 23
2019
Q3
$868M Sell
3,616,782
-204,890
-5% -$56.1M 1.7% 24
2019
Q2
$1.08B Buy
3,821,672
+1,921,814
+101% +$525M 1.96% 20
2019
Q1
$545M Sell
1,899,858
-143,639
-7% -$41.5M 0.98% 35
2018
Q4
$537M Sell
2,043,497
-279,693
-12% -$76.9M 1.05% 34
2018
Q3
$637M Sell
2,323,190
-118,676
-5% -$30.8M 1.01% 35
2018
Q2
$581M Buy
2,441,866
+19,494
+0.8% +$4.51M 0.94% 36
2018
Q1
$532M Sell
2,422,372
-53,255
-2% -$12.5M 0.85% 38
2017
Q4
$557M Sell
2,475,627
-105,011
-4% -$22.4M 0.83% 38
2017
Q3
$490M Sell
2,580,638
-4,064,665
-61% -$774M 0.74% 40
2017
Q2
$1.25B Sell
6,645,303
-891,661
-12% -$160M 1.9% 22
2017
Q1
$1.25B Sell
7,536,964
-516,064
-6% -$82.1M 1.88% 21
2016
Q4
$1.16B Sell
8,053,028
-361,879
-4% -$48.5M 1.74% 26
2016
Q3
$1.05B Sell
8,414,907
-160,604
-2% -$20.7M 1.61% 28
2016
Q2
$1.13B Buy
8,575,511
+1,306,670
+18% +$179M 1.72% 26
2016
Q1
$1.01B Sell
7,268,841
-130,852
-2% -$17.5M 1.54% 27
2015
Q4
$1.03B Sell
7,399,693
-145,444
-2% -$20M 1.54% 28
2015
Q3
$1.06B Sell
7,545,137
-157,568
-2% -$23.7M 1.62% 30
2015
Q2
$1.26B Sell
7,702,705
-136,303
-2% -$21.8M 1.72% 22
2015
Q1
$1.21B Sell
7,839,008
-349,112
-4% -$49.7M 1.64% 26
2014
Q4
$1.03B Sell
8,188,120
-2,572,810
-24% -$318M 1.38% 31
2014
Q3
$1.29B Sell
10,760,930
-1,007,086
-9% -$116M 1.75% 23
2014
Q2
$1.27B Sell
11,768,016
-1,444,750
-11% -$149M 1.7% 22
2014
Q1
$1.32B Sell
13,212,766
-4,256,044
-24% -$385M 1.88% 20
2013
Q4
$1.61B Buy
17,468,810
+103,335
+0.6% +$9.18M 2.34% 11
2013
Q3
$1.45B Sell
17,365,475
-66,778
-0.4% -$5.72M 2.32% 14
2013
Q2
$1.43B Buy
+17,432,253
New +$1.3B 2.4% 11

Other funds holding ELV

Barrow, Hanley, Mewhinney & Strauss's ELV Position: Q1 2026 in Review

Barrow, Hanley, Mewhinney & Strauss reduced its Elevance Health (ELV) stake by 19% in Q1 2026, selling an estimated $32.3M and leaving 407,168 shares worth $119M. The position accounts for 0.39% of the portfolio, ranked #74.

Barrow, Hanley, Mewhinney & Strauss first reported a position in ELV in Q2 2013 and has held it in 52 quarters since. The position peaked at $1.61B in Q4 2013. 1,462 funds tracked by Wall St. Rank hold ELV as of Q1 2026.

  • Barrow, Hanley, Mewhinney & Strauss held 407,168 shares of Elevance Health worth $119M as of Q1 2026.
  • Barrow, Hanley, Mewhinney & Strauss sold 98,371 Elevance Health shares in Q1 2026, an estimated $32.3M.
  • Elevance Health made up 0.39% of Barrow, Hanley, Mewhinney & Strauss's portfolio in Q1 2026, its #74 holding.
  • Barrow, Hanley, Mewhinney & Strauss first reported a position in Elevance Health in Q2 2013 and has held it in 52 quarters since.
  • Barrow, Hanley, Mewhinney & Strauss's Elevance Health position peaked at $1.61B in Q4 2013.
  • 1,462 funds tracked by Wall St. Rank held Elevance Health as of Q1 2026.

Based on Barrow, Hanley, Mewhinney & Strauss's 13F filing for Q1 2026, filed 13 May 2026.